| Literature DB >> 33181638 |
Wei-Chun Chang1,2, Chi-Yen Wang1, Yutsung Cheng1,2, Yu-Po Hung1, Tzu-Hsiang Lin1, Wei-Jhong Chen1, Chieh-Shou Su1,3, Chiann-Yi Hsu4, Tsun-Jui Liu1,3, Wen-Lieng Lee1,3.
Abstract
Although plantar thermography can evaluate the immediate perfusion result after an endovascular therapy (EVT) has been performed, a relevant wound outcome study is still lacking.This study was to investigate whether angiosome-based plantar thermography could predict wound healing and freedom from major amputation after EVT in patients with critical limb ischemia (CLI).All 124 patients with CLI (Rutherford category 5 and 6) who underwent EVT from January 2017 to February 2019 were prospectively enrolled. All patients received thermography both before and after EVT. Both wound healing and freedom from major amputation at the 6-month follow-up period were recorded. There were 61 patients in the healing group and 63 patients in the non-healing group, whereas the major amputation total was 14 patients. The mean pre- and post-EVT temperature of the foot was significantly higher in the healing group than in the non-healing group (30.78 °C vs 29.42 °C, P = .015; and 32.34 °C vs 30.96 °C, P = .004, respectively). DIFF2 was significantly lower in the non-healing group (-1.38 vs -0.90, P = .009). DIFF1 and DIFF2 were significantly lower in the amputation group (-1.85 °C vs -1.11 °C, P = .026; and -1.82 °C vs -1.08 °C, P = .004). Multivariate analysis showed that DIFF2 stood out as an independent predictor for freedom from major amputation (hazard ratio 0.51, P = .045). Receiver operating characteristic curve analysis showed a DIFF2 cut-off value of -1.30 °C, which best predicts freedom from major amputation.Plantar thermography is associated with wound healing and helps predict freedom from major amputation in CLI patients undergoing EVT.Entities:
Mesh:
Year: 2020 PMID: 33181638 PMCID: PMC7668514 DOI: 10.1097/MD.0000000000022391
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1Typical thermal images of a patient's lower limb before and after successful EVT. Panel A: plantar aspect of right foot before EVT. The letters A-D depict angiosome-based thermographic zones used in this study. All zones, particularly in the digits, were hypothermic as compared with the normothermic zone in the lower leg. Panel B: Doral aspect of right foot. Letter E depicts zone of measurement in this study. It was also hypothermic, particularly in the digits. Panels C and D: Plantar and dorsal aspects of thermal images one day after successful EVT. All zones were normothermic.
Baseline demographic data.
| All patients N = 124 | Healing in 6-M Group N = 61 | Non-Healing in 6-M Group N = 63 | ||
| Age (yr) | 73.0 (63–80) | 71.0 (58–84) | 73.0 (67–78) | .540 |
| Gender-Male, N (%) | 75 (60.5%) | 42 (68.9%) | 33 (52.4%) | .091 |
| Body mass index, kg/m2 | 22.9 (19.8–26.4) | 24.4 (20.1–26.9) | 21.9 (19.4–26.1) | .180 |
| Current smoker, N (%) | 9 (7.3%) | 6 (9.8%) | 3 (4.8%) | .493 |
| Hypertension, N (%) | 95 (76.6%) | 45 (73.8%) | 50 (79.4%) | .601 |
| Diabetes mellitus, N (%) | 87 (70.2%) | 40 (65.6%) | 47 (74.6%) | .367 |
| Hyperlipidemia, N (%) | 32 (25.8%) | 11 (18%) | 21 (33.3%) | .082 |
| Chronic lung disease, N (%) | 13 (10.5%) | 9 (14.8%) | 4 (6.3%) | .217 |
| Congestive heart failure, N (%) | 44 (35.5%) | 20 (32.8%) | 24 (38.1%) | .667 |
| Coronary artery disease, N (%) | 44 (35.5%) | 19 (31.1%) | 25 (39.7%) | .421 |
| Old myocardial infarction, N (%) | 1 (0.8%) | 0 (0.0%) | 1 (1.6%) | 1.000 |
| History of CABG, N (%) | 6 (4.8%) | 2 (3.3%) | 4 (6.3%) | .680 |
| Previous PCI, N (%) | 31 (25%) | 14 (23%) | 17 (27.0%) | .756 |
| History of peripheral artery disease, N (%) | 40 (32.3%) | 16 (26.2%) | 24 (38.1%) | .222 |
| Previous lower limb bypass, N (%) | 5 (4.0%) | 2 (3.3%) | 3 (4.8%) | 1.000 |
| Prior stroke or TIA, N (%) | 17 (13.7%) | 6 (9.9%) | 11 (17.5%) | .331 |
| Current dialysis, N (%) | 43 (34.7%) | 17 (27.9%) | 26 (41.3%) | .168 |
| Chronic kidney disease∗, N (%) | 69 (55.6%) | 28 (45.9%) | 41 (65.1%) | .049 |
| Atrial fibrillation, N (%) | 18 (14.5%) | 6 (9.8%) | 12 (19.0%) | .230 |
| Collagen vascular disease, N (%) | 10 (8.1%) | 4 (6.6%) | 6 (9.5%) | .744 |
| Creatinine (mg/dL) | 1.4 (0.9–5) | 1.2 (0.8–4.5) | 1.8 (1–5.3) | .229 |
| Estimated GFR (ml/min) | 44.0 (10.4–84) | 63.1 (10.2–88.9) | 35.6 (10.5–74.9) | .185 |
| HbA1C (mg/dL) | 6.9 (6.1–8.7) | 7.0 (6.2–9.2) | 6.9 (6–8.4) | .333 |
| LDL cholesterol, mg/dL | 75.5 (56–101.8) | 77.0 (59–105) | 74.0 (54–101) | .612 |
| Hemoglobin, g/dL | 10.1 (8.6–11.7) | 10.8 (8.9–12.9) | 9.7 (8.5–10.7) | .004 |
| ABI | 0.8 (0.6–1) | 0.8 (0.6–1) | 0.8 (0.6–1) | .664 |
| Rutherford classification, N (%) | <.001 | |||
| Category 5 | 54 (43.5%) | 37 (60.7%) | 17 (27%) | |
| Category 6 | 70 (56.5%) | 24 (39.3%) | 46 (73.0%) | |
| University of Texas classification, N (%) | .057 | |||
| Grade 0 | 11 (8.9%) | 8 (13.1%) | 3 (4.8%) | |
| Grade 1 | 43 (34.7%) | 25 (41%) | 18 (28.6%) | |
| Grade 2 | 29 (23.4%) | 14 (23%) | 15 (23.8%) | |
| Grade 3 | 41 (33.1%) | 14 (23%) | 27 (42.9%) | |
| Infection, N (%) | 66 (53.2%) | 30 (49.2%) | 36 (57.1%) | .479 |
| Medications,N (%) | ||||
| Aspirin | 102 (82.3%) | 52 (85.2%) | 50 (79.4%) | .534 |
| Clopidogrel | 110 (88.7%) | 52 (85.2%) | 58 (92.1%) | .360 |
| Cilostazol | 80 (64.5%) | 43 (70.5%) | 37 (58.7%) | .238 |
| Pentoxifylline | 7 (5.6%) | 4 (6.6%) | 3 (4.8%) | .715 |
| Warfarin or NOAC | 11 (8.9%) | 5 (8.2%) | 6 (9.5%) | 1.000 |
| ACEI/ARB | 54 (43.5%) | 24 (39.3%) | 30 (47.6%) | .454 |
| Statin | 74 (59.7%) | 36 (59.0%) | 38 (60.3%) | 1.000 |
| Beta blocker | 38 (30.6%) | 14 (23%) | 24 (38.1%) | .102 |
| Calcium channel blocker | 61 (49.2%) | 32 (52.5%) | 29 (46.0%) | .592 |
| Insulin | 32 (25.8%) | 16 (26.2%) | 16 (25.4%) | 1.000 |
| Prostaglandin E1 | 35 (28.2%) | 19 (31.1%) | 16 (25.4%) | .609 |
Lesion characteristics and clinical outcomes.
| All Patients N = 124 | Healing in 6-M Group N = 61 | Non-Healing in 6-M Group N = 63 | ||
| Aortoiliac lesion, N (%) | 9 (7.3%) | 1 (1.6%) | 8 (12.7%) | .033 |
| TASC II classification | 1.000 | |||
| TASC C | 2 (22.2%) | 0 (0%) | 2 (25%) | |
| TASC D | 7 (77.8%) | 1 (100%) | 6 (75%) | |
| CTO | 4 (3.2%) | 1 (1.6%) | 3 (4.8%) | .619 |
| Vessel calcification∗ | .268 | |||
| Grade 2 | 2 (22.2%) | 0 (0%) | 2 (25%) | |
| Grade 3 | 3 (33.3%) | 0 (0%) | 3 (37.5%) | |
| Femoropopliteal lesion, N (%) | 76 (61.3%) | 33 (54.1%) | 43 (68.3%) | .152 |
| TASC II classification | .978 | |||
| TASC C | 22 (28.9%) | 9 (27.3%) | 13 (30.2%) | |
| TASC D | 46 (60.5%) | 20 (60.6%) | 26 (60.5%) | |
| CTO | 22 (17.7%) | 13 (21.3%) | 9 (14.3%) | .430 |
| Vessel calcification | .745 | |||
| Grade 3 | 17 (13.7%) | 8 (13.1%) | 9 (14.3%) | |
| Grade 4 | 21 (16.9%) | 9 (14.8%) | 12 (19%) | |
| Infra-popliteal lesion N (%) | 120 (96.8%) | 60 (98.4%) | 60 (95.2%) | .619 |
| TASC II classification | .768 | |||
| TASC C | 36 (29%) | 17 (27.9%) | 19 (30.2%) | |
| TASC D | 70 (56.4%) | 34 (55.7%) | 36 (57.1%) | |
| CTO | 101 (81.5%) | 51 (83.6%) | 50 (79.4%) | .707 |
| Vessel calcification | .299 | |||
| Grade 3 | 17 (13.7%) | 7 (11.5%) | 10 (15.9%) | |
| Grade 4 | 27 (21.8%) | 12 (19.7%) | 15 (23.8%) | |
| Run-off vessel numbers (0/1/2/3), N | ||||
| Before EVT | 31/40/37/14 | 16/16/21/8 | 15/24/16/6 | .459 |
| After EVT | 1/28/63/30 | 0/9/35/17 | 1/19/28/13 | .117 |
| Median run-off vessel numbers, N | ||||
| Before EVT | 1.0 (0–2) | 1.0 (0–2) | 1.0 (0.5–2) | .447 |
| After EVT | 2.0 (2–2.3) | 2.0 (2–3) | 2.0 (1–2) | .050 |
| Occlusion of plantar arch, N (%) | 46 (38.7%) | 20 (33.3%) | 26 (44.1%) | .311 |
| Procedure success | 113 (91.1%) | 57 (93.4%) | 56 (88.9%) | .565 |
| Stenting | 42 (33.9%) | 15 (24.6%) | 27 (42.9%) | .050 |
| Drug coating balloon | ||||
| Femoropopliteal | 19 (15.3%) | 7 (11.5%) | 12 (19.0%) | .357 |
| Infra-popliteal | 19 (15.3%) | 11 (18.0%) | 8 (12.7%) | .565 |
| 18-month clinical outcome | ||||
| Target Lesion Revascularization | 18 (14.5%) | 9 (14.8%) | 9 (14.3%) | 1.000 |
| All-cause mortality | 29 (23.4%) | 8 (13.1%) | 21 (33.3%) | .014 |
Comparison of thermographic parameters between patients with/without wound healing or major amputation at 6 months.
| All patients N = 124 | Healing in 6-mo Group N = 61 | Non-Healing in 6-mo Group N = 63 | ||
| Mean pre-EVT temperature of whole foot (°C) | 30.05 (28.00–31.87) | 30.78 (28.94–32.38) | 29.42 (26.84–31.38) | .015 |
| Mean post-EVT temperature of whole foot (°C) | 31.67 (29.30–32.80) | 32.34 (30.48–33.23) | 30.96 (28.74–32.48) | .004 |
| Post- minus pre-EVT temperature of whole foot (°C) | 1.30 (−0.65–3.24) | 1.30 (−0.64–3.46) | 1.30 (−0.78–3.12) | .994 |
| DIFF1 (°C) | −1.13 (−1.69–0.79) | −1.12 (−1.70–0.74) | −1.14 (−1.68–0.80) | .605 |
| DIFF2 (°C) | −1.12 (−1.78–0.69) | −0.90 (−1.52–0.59) | −1.38 (−1.82–0.94) | .009 |
| DIFF2 minus DIFF1 (°C) | 0.00 (−0.52–0.57) | 0.10 (−0.26–0.59) | −0.14 (−0.68–0.46) | .070 |
| All patients N = 124 | No-Major Amputation N = 110 | Major Amputation N = 14 | ||
| Mean pre-EVT temperature of whole foot (°C) | 30.05 (28.00–31.87) | 30.05 (27.95–31.76) | 30.03 (28.35–33.17) | .567 |
| Mean post-EVT temperature of whole foot (°C) | 31.67 (29.30–32.80) | 31.72 (29.38–32.95) | 31.00 (28.94–32.35) | .407 |
| Post- minus pre-EVT temperature of whole foot (°C) | 1.30 (−0.65–3.24) | 1.38 (−0.63–3.66) | 0.47 (−1.10–1.79) | .398 |
| DIFF1 (°C) | −1.13 (−1.69–0.79) | −1.11 (−1.60–0.76) | −1.85 (−2.67–0.99) | .026 |
| DIFF2 (°C) | −1.12 (−1.78–0.69) | −1.08 (−1.67–0.68) | −1.82 (−2.21–1.45) | .004 |
| DIFF2 minus DIFF1 (°C) | 0.00 (−0.52–0.57) | 0.01 (−0.40–0.57) | −0.25 (−1.10–0.96) | .525 |
Predictors for wound healing.
| Univariate analysis | Multivariate analysis | |||||
| HR | 95% CI | HR | 95% CI | |||
| Age (yr) | 1.00 | (0.98–1.02) | .678 | |||
| Gender (Male vs Female) | 1.49 | (0.87–2.57) | .147 | |||
| Current smoking | 1.33 | (0.57–3.09) | .510 | |||
| Current dialysis | 0.70 | (0.40–1.22) | .211 | |||
| Chronic kidney disease | 0.57 | (0.34–0.94) | .027 | 0.62 | (0.36–1.07) | .086 |
| Hemoglobin | 1.12 | (1.02–1.24) | .020 | 1.02 | (0.90–1.15) | .788 |
| Rutherford classification (6 vs 5) | 0.43 | (0.25–0.72) | .001 | 0.46 | (0.26–0.82) | .008 |
| University of Texas classification | ||||||
| Grade 0 as reference | ||||||
| Grade 1 | 0.57 | (0.26–1.26) | .166 | |||
| Grade 2 | 0.50 | (0.21–1.20) | .121 | |||
| Grade 3 | 0.35 | (0.15–0.84) | .019 | |||
| Infection | 0.78 | (0.47–1.28) | .326 | |||
| Occluded plantar arch | 0.57 | (0.34–0.98) | .044 | 0.58 | (0.33–1.01) | .055 |
| Run-off vessel number after EVT | 1.72 | (1.19–2.51) | .004 | 1.65 | (1.09–2.51) | .018 |
| Prostaglandin E1 use | 1.21 | (0.70–2.08) | .492 | |||
| Femoropopliteal drug-coating balloon | 0.57 | (0.26–1.25) | .158 | |||
| Infra-popliteal drug-coating balloon | 1.02 | (0.53–1.95) | .961 | |||
| Mean pre-EVT temperature of whole foot | 1.07 | (0.98–1.17) | .111 | |||
| Mean post-EVT temperature of whole foot | 1.11 | (1.01–1.21) | .026 | 1.07 | (0.96–1.19) | .218 |
| DIFF1 | 1.10 | (0.92–1.31) | .310 | |||
| DIFF2 | 1.46 | (1.01–2.09) | .041 | 1.06 | (0.73–1.52) | .774 |
Predictors for major amputation.
| Univariate analysis | Multivariate analysis | |||||
| HR | 95% CI | HR | 95% CI | |||
| Age (yr) | 0.99 | (0.96–1.03) | .721 | |||
| Gender (Male vs Female) | 0.84 | (0.29–2.43) | .751 | |||
| Current smoking | 1.02 | (0.13–7.79) | .986 | |||
| Current dialysis | 4.07 | (1.36–12.21) | .012 | 2.30 | (0.75–7.10) | .146 |
| Chronic kidney disease | 3.30 | (0.92–11.85) | .067 | |||
| Hemoglobin | 0.65 | (0.46–0.91) | .014 | 0.68 | (0.47–0.99) | .047 |
| Rutherford classification (6 vs 5) | 4.87 | (1.09–21.78) | .038 | 1.36 | (0.29–6.45) | .698 |
| University of Texas classification | ||||||
| Grade 1 as reference | ||||||
| Grade 2 | 3.00 | (0.27–33.09) | .370 | |||
| Grade 3 | 13.05 | (1.68–101.20) | .014 | |||
| Infection | 12.07 | (1.58–92.27) | .016 | 11.78 | (1.40–98.95) | .023 |
| Occluded plantar arch | 1.60 | (0.56–4.57) | .378 | |||
| Run-off vessel number after EVT | 0.87 | (0.42–1.78) | .693 | |||
| Prostaglandin E1 use | 0.20 | (0.03–1.53) | .121 | |||
| Femoropopliteal drug-coating balloon | 0.43 | (0.06–3.26) | .412 | |||
| Infra-popliteal drug-coating balloon | 0.38 | (0.05–2.92) | .353 | |||
| Mean pre-EVT temperature of whole foot | 1.08 | (0.90–1.29) | .409 | |||
| Mean post-EVT temperature of whole foot | 0.98 | (0.82–1.16) | .795 | |||
| DIFF1 | 0.91 | (0.79–1.06) | .229 | |||
| DIFF2 | 0.50 | (0.31–0.83) | .007 | 0.51 | (0.27–0.98) | .045 |
Figure 2Receiver operating characteristic curve analysis for DIFF2 in predicting freedom from major amputation. At a DIFF2 value of ≧ -1.3 °C, it predicted freedom from major amputation with a sensitivity of 70.5%, specificity of 54.0%, positive predictive value of 59.7%, and negative predictive value of 65.4% (area under curve 0.738, 95% confidence interval [CI],0.601-0.876; P = .004).
Predictors for mortality.
| Univariate analysis | Multivariate analysis | |||||||
| HR | 95% CI | HR | 95% CI | |||||
| Age (yr) | 1.03 | (1.00–1.07) | .037 | 1.05 | (1.01–1.09) | .013 | ||
| Gender (male vs female) | 0.85 | (0.40–1.84) | .687 | |||||
| Body mass index, kg/m2 | 0.89 | (0.81–0.97) | .008 | 0.92 | (0.82–1.03) | .154 | ||
| Chronic lung disease | 1.80 | (0.73–4.43) | .203 | |||||
| Congestive heart failure | 1.88 | (0.91–3.90) | .090 | |||||
| Coronary artery disease | 1.69 | (0.81–3.54) | .161 | |||||
| Currently on dialysis | 2.69 | (1.29–5.61) | .008 | 4.38 | 10.18) | .001 | ||
| GFR (mL/min) | 0.99 | (0.98–1.00) | .098 | |||||
| Low density lipoprotein, mg/dL | 0.99 | (0.98–1.00) | .103 | |||||
| Rutherford classification (6 vs 5) | 2.08 | (0.91–4.79) | .083 | |||||
| Stenting | 2.28 | (1.09–4.76) | .028 | 1.56 | (0.64–3.81) | .328 | ||
| Femoropopliteal drug-coating balloon | 1.07 | (0.37–3.07) | .906 | |||||
| Infra-popliteal drug-coating balloon | 0.34 | (0.08–1.42) | .138 | |||||
| Mean pre-EVT temperature of whole foot | 0.89 | (0.80–0.99) | .039 | 0.96 | (0.87–1.06) | .391 | ||
| Mean post-EVT temperature of whole foot | 0.88 | (0.78–0.99) | .029 | |||||
| DIFF1 | 1.11 | (0.84–1.47) | .474 | |||||
| DIFF2 | 0.84 | (0.58–1.23) | .365 | |||||
Figure 3Kaplan–Meier survival curves of post-EVT wound healing, freedom from major amputation and overall survival in all CLI patients. Panel A: Overall wound healing was 28.4% and 56.7% at 3 and 6 months respectively; Panel B: Freedom from major amputation was 89.9% and 86.9% at 3 and 6 months respectively; Panel C: Overall survival was 69.6% and 62.6% at 12 and 18 months respectively.